Last reviewed · How we verify
isobaric bupvacaine in Peribulbar block
Isobaric bupvacaine in Peribulbar block, developed by Cairo University, is a marketed anesthetic used primarily in ophthalmic surgeries. The drug maintains a competitive edge due to its key composition patent, which is set to expire in 2028. The primary risk to the drug's market position is the potential for increased competition following the patent expiry.
At a glance
| Generic name | isobaric bupvacaine in Peribulbar block |
|---|---|
| Also known as | control group |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isobaric bupvacaine in Peribulbar block CI brief — competitive landscape report
- isobaric bupvacaine in Peribulbar block updates RSS · CI watch RSS
- Cairo University portfolio CI